In addition to elucidating the roles of IP3R2 in cardiac hypertrophy, their findings also underscored the effectiveness of an IP3R antagonist in mitigating alterations in Ca2+i transients induced by IP3 stimulation. Here, ITPR1 is linked to cardiac hypertrophy.